IN MEMORIAM, CO-FOUNDER & EXECUTIVE CHAIRMAN EMERITUS
Marc Cohen was C4 Therapeutics’ visionary co-founder and Executive Chairman who passed away in June 2022. Throughout his life, Marc believed in “doing well by doing good,” which led him to invest in promising science that had the potential to help patients. He had a special talent for seeing the potential in revolutionary ideas before others, which we saw with the creation of C4T. He believed in the potential of Targeted Protein Degradation science and was one of the first to see that it could become a new kind of medicine to fight cancer and other diseases. Marc’s vision was matched only by his endless energy to take these insights and harness them into medicines.
The numerous biotechnology companies he founded over the course of his career are a testament to his passion for using his gifts to help advance breakthrough science to treatments for patients. In addition to co-founding C4 Therapeutics in 2015, Marc also co-founded Regenacy Pharmaceuticals, where he served as Executive Chairman, NextRNA Therapeutics, where he also served as CEO and Executive Chairman, and AI Proteins. He advanced therapeutic discoveries through his leadership at Frequency Therapeutics, Acetylon Pharmaceuticals, Mana Therapeutics, OncoPep and Dynamic Cell Therapies. He also served as Co-founder, Chairman and Chief Executive of Bublup, Inc., co-CEO, of Cobro Ventures, Inc., and co-founder and CEO of OPNET Technologies. Marc was also a long-time supporter of Dana Farber Cancer Institute, where he co-founded the Dana Farber Innovations Research Fund.
Ken Anderson, M.D. is a co-founder and has served as a member of our Board since December 2015. Dr. Anderson has also served as the Kraft Family Professor of Medicine at Harvard Medical School since 2002, as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively. Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. Dr. Anderson serves on the following boards of directors: Window Therapeutics, a biotechnology company developing therapies that advance treatment options for patients with cancer and other serious diseases, since January 2021; Dynamic Cell Therapies, Inc. (formerly Raqia Therapeutics, Inc.), a CAR-T cell therapies company for cancer and other diseases, since September 2020; and Starton Therapeutics, Inc., a biotechnology company focused on blood cancer treatments, since September 2020. Dr. Anderson holds an M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute.
Laura Bessen, M.D., has served as a member of our Board of Directors since August 2022. Dr. Bessen currently serves as managing partner at Maxsam Advisors LLC where she provides strategic clinical and medical affairs advice to clients across the biotechnology and pharmaceutical industries. Previously, she held roles of increasing responsibility over a 15-year career at Bristol Myers Squibb (BMS), most recently as Vice President, Head of US Medical. During her tenure at BMS, she helped launch 11 new products including Opdivo®, Yervoy®, elotuzomab, and Eliquis® and co-led BMS’ partnership with Gilead to develop Atripla®. Dr. Bessen also co-led the development of BMS product commercialization model, life cycle management and launch investment principles. Earlier in her career, Dr. Bessen served in medical affairs roles at DuPont Pharmaceuticals. She currently serves on the Board of Directors of Artiva Biotherapeutics, an oncology company developing and advancing off-the-shelf, allogeneic natural killer cell therapies for patients with hematologic cancers or solid tumors. Dr. Bessen received her M.D. degree from New York University School of Medicine and B.S. in biochemistry from the State University of New York at Binghamton.
Bruce Downey has served as a member of our Board of Directors since December 2015. Previously, Bruce was Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc. (until its acquisition by Teva in 2008), a global generic pharmaceutical manufacturer. He has served on a part-time basis as a Partner of NewSpring Health Capital II, L.P., a venture capital firm, since April 2009. Prior to Barr Pharmaceuticals, Bruce was a practicing attorney for 20 years, working in both the private sector and for the federal government, including the U.S. Department of Justice and the U.S. Department of Energy. In addition, he serves on the boards of directors of OncoPep, Inc., a biotechnology company, and Cardinal Health, Inc., a healthcare services company since April 2011 and July 2009 respectively. Bruce previously served on the board of directors of Melinta Therapeutics, Inc., a biopharmaceutical firm, and Momenta Pharmaceuticals, a biotechnology company acquired by Johnson & Johnson. He holds a B.S. in Economics from Miami University and a J.D. from Ohio State University.
Donna Grogan, M.D., has served as a member of our Board of Directors since August 2022. Dr. Grogan currently serves as Principal of Grogan Consulting LLC where she supports clients across drug development, regulatory strategy, trial design and data interpretation. Between September 2013 and June 2019, Dr. Grogan served as Chief Medical Officer of Clementia Pharmaceuticals, which was acquired by Ipsen in April 2019. She previously served as Chief Medical Officer for several HealthCare Ventures portfolio companies including Anexon, Apofore, and DecImmune. Between February 2007 and August 2011, Dr. Grogan served as Chief Medical Officer, Senior Vice President Clinical Development at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. Earlier in her career, she held roles of increasing responsibility at Sepracor Inc. where she was involved in multiple high-profile product approvals including Lunesta®, Xopenex HFA®, and Brovana™. Dr. Grogan previously served as a board member, including membership on the Compensation Committee and the Scientific Committee, of Momenta Pharmaceuticals until it was acquired by J&J in October 2020. She holds a M.D. from University of Illinois College of Medicine and a B.A. from College of the Holy Cross.
Andrew Hirsch joined C4 Therapeutics in September 2020 and serves as our President, Chief Executive Officer, and a member of our Board of Directors. Previously, Andrew was Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals, Inc. Andrew has more than 25 years of experience in a range of strategic and operating roles in the biotechnology sector, previously serving as President and Chief Executive Officer of BIND Therapeutics, Inc. Prior to being named President and Chief Executive Officer, Andrew held several other leadership positions at BIND, including Chief Operating Officer and Chief Financial Officer. Before joining BIND, Andrew was Chief Financial Officer at Avila Therapeutics, Inc. from June 2011 until its acquisition by Celgene Corporation. From 2002 to 2011, Andrew held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team. Since May 2017, Andrew has served on the Board of Directors of Editas Medicine, Inc. Andrew holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.
Utpal Koppikar, MBA, has served as a member of our Board of Directors since March 2022. Utpal is currently the Chief Financial Officer of Verily, an Alphabet backed company focused on precision health. Prior to joining Verily, he served as Executive Vice President and Chief Financial Officer at Atara Biotherapeutics from June 2018 to March 2022, where he oversaw the finance, information technology and investor relations functions and he guided the company’s strategy as a member of its senior leadership team. Earlier in his career, Utpal held several senior financial leadership positions at Gilead Sciences (Gilead), including Vice President of Corporate and Operations Finance. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma and played a key role as Gilead’s Vice President of Finance Europe, Middle East and Australia in the launch of multiple HIV and HCV product launches. Before joining Gilead, Utpal served in multiple finance roles of increasing responsibility at Amgen. Utpal previously served as a board member of Flexion Therapeutics Inc. until its sale to Pacira Biosciences in November 2021. He holds an MBA in finance from UCLA’s Anderson School of Management., an M.S. in aeronautical engineering from Stanford University and a B.S. in aerospace engineering from the University of Maryland.
Malcolm Salter has served as a member of our Board of Directors since December 2015. Malcolm is the James J. Hill Professor, Emeritus, at the Harvard Business School. Since joining the Harvard Business School faculty in 1967, his teaching and research has focused on issues of corporate strategy and governance. He currently serves on the following boards of directors: AI Proteins, a biotechnology company focused on the design and engineering of synthetic mini-protein therapeutics, since 2022; NextRNA, Inc., a biotechnology company focused on developing the next generation of RNA-directed therapeutics, since February 2021; and Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since September 2020. From 1986 to 2006, he served as president of Mars & Co., a global strategy-consulting firm. He is a former Trustee of the Dana-Farber Cancer Institute. Mr. Salter holds an A.B., M.B.A., and a D.B.A. from Harvard University.
Dr. Scott A. Armstrong is Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute, Associate Chief, Department of Hematology/Oncology, Boston Children’s Hospital, and the David G. Nathan Professor of Pediatrics at Harvard Medical School. Dr. Armstrong received his M.D. and Ph.D. from the University of Texas Southwestern Medical School in Dallas, Texas. He performed his residency and fellowship in pediatric hematology/oncology at Children’s Hospital Boston, the Dana Farber Cancer Institute, and Harvard Medical School. The major focus of his career has been on delineating the biology of leukemia and the development of new therapeutic approaches for cancer. His group studies how chromatin-associated complexes control cancer-causing gene expression and has used this understanding to develop small molecule approaches that he continues to pursue. This work has led to the development of clinical trials that are being assessed in adults and children with cancer. His work has been recognized by a number of awards including the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center, the E. Mead Johnson Award for Outstanding Research in Pediatrics and the Dameshek Prize from the American Society of Hematology. He is an elected member of the National Academy of Medicine (NAM), American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), and is a fellow of the Association for the Advancement of Science.
Ross Levine, M.D., is a Member of the Human Oncology and Pathogenics Program and an Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research, a Professor of Medicine at Weill Cornell Medical College, and is the Director of the MSK Center for Hematologic Malignancies. Dr. Levine was born and raised in the New York area, and then received his AB from Harvard College and a M.D. from Johns Hopkins. Dr. Levine served as an Resident in Internal Medicine at the MGH and subsequently as a Hematology-Oncology Fellow at DFCI. His laboratory has identified MPN predisposition alleles and characterized somatic genetic alterations in MPN patients, which has improved our understanding of the genetic basis of MPNs. In addition his lab has performed preclinical studies of JAK kinase inhibitors and HSP90 inhibitors. His lab also investigates the role of somatic mutations in epigenetic modifiers in AML and mechanisms of sensitivity and resistance to epigenetic therapies. He serves on the editorial board of Blood, JCI, and on the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society. He has earned the Dameshek Prize from the American Society of Hematology, a Scholar Award from the Leukemia and Lymphoma Society, a Young Investigator Award from the American Society of Clinical Oncology, a Scholar Award from the American Society of Hematology, the Boyer Award for Clinical Investigation from MSKCC, a Clinical Scientist Development Award from the Doris Duke Charitable Foundation and a NCI Outstanding Investigator R35 award for his work on cancer epigenetics. In 2011 he was elected to the American Society of Clinical Investigation and in 2018 to the Association of American Physicians.
Christopher Kirk, Ph.D., is co-founder, President and Chief Scientific Officer, of Kezar Life Sciences (NASDQ : KZR), a clinical-stage, San Francisco Bay Area-based biotechnology company focused on drug discovery and development in autoimmunity and oncology. Prior to Kezar, he was the Vice President of Research at Onyx Pharmaceuticals where he played a key leadership role in the discovery and development of 2 proteasome inhibitors, carfilzomib (KYPROLIS™), currently approved for the treatment of multiple myeloma, and oprozomib, currently in Phase 2 testing. Dr. Kirk has authored multiple publications in journals including Cell, Nature Medicine, and Nature Reviews and is listed as an inventor on over 25 patents. He sits on the scientific advisory board at Karyopharm Therapeutics, Inc., Avidity Biosciences LLC, Rain Therapeutics, Inc., and the Institute of Applied Clinical Science at the M.D. Anderson Cancer Center. Dr. Kirk received his B.S. degree in Biochemistry from University of California, Davis, and his Ph.D. degree in Cellular and Molecular Biology from the University of Michigan.
Dr. Ryan Corcoran is the Director of the Gastrointestinal Cancer Center Program and the Scientific Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center. He is an Associate Professor of Medicine at Harvard Medical School. Dr. Corcoran received his A.B. from Princeton University, and his M.D./Ph.D. from Stanford University. He completed his residency in Internal Medicine at the Massachusetts General Hospital and his fellowship in Medical Oncology at the Dana Faber Cancer Institute and the Massachusetts General Hospital Cancer Center. Dr. Corcoran directs a research laboratory focused on personalized cancer medicine: the development of therapeutic strategies that target the specific mutations driving individual patients’ tumors. His work focuses on understanding the molecular determinants of response or resistance to anti-cancer therapies. Dr. Corcoran’s laboratory is also studying new ways to utilize liquid biopsy, and specifically analysis of circulating tumor DNA, in the clinic to optimize how we deliver cancer care to individual patients. Dr. Corcoran is a member of the National Cancer Institute Colorectal Cancer Task Force and the Rectal Cancer Task Force, and an elected member of the American Society for Clinical Investigation (ASCI).
Ken Anderson, M.D. is a co-founder and has served as a member of our Board since December 2015. Dr. Anderson has also served as the Kraft Family Professor of Medicine at Harvard Medical School since 2002, as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively. Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. Dr. Anderson serves on the following boards of directors: Window Therapeutics, a biotechnology company developing therapies that advance treatment options for patients with cancer and other serious diseases, since January 2021; Dynamic Cell Therapies (formerly Raqia Therapeutics, Inc.), a CAR-T cell therapies company for cancer and other diseases, since September 2020; and Starton Therapeutics, Inc., a biotechnology company focused on blood cancer treatments, since September 2020. Dr. Anderson holds an M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute.